Q2 2026 Peptide News

The second quarter of 2026 has been a bustling period for peptide drug development, with continued growth in obesity and metabolic health and new developments in oncology and pain management. We’ve highlighted advancements spanning Phase 2/3 data in chronic weight management as well as targeted peptide treatments tackling oncology, rare bone disorders, and chronic inflammation.

Oncology

Verrica Pharmaceuticals announced upcoming Phase 2 clinical data demonstrating the therapeutic potential of VP-315, an investigational first-in-class oncolytic peptide. The presentation highlights the drug's unique ability to leverage localized administration to trigger a systemic immune response against basal cell carcinoma lesions.

Researchers at UC San Diego have discovered a naturally occurring peptide that may inhibit melanoma progression. The peptide disrupts the defensive mechanisms that tumor cells use to evade detection by the host immune system.

FluoGuide has reported highly successful Phase 2 results utilizing FG001, a targeted fluorophore peptide conjugate designed to guide oncology surgeries. FG001 binds specifically to uPAR, a receptor highly expressed on cancer cells, causing the tumor tissue to light up during surgical resection.

Obesity & Metabolic Health

Apotex has achieved a major milestone by securing Health Canada's first approval for Sevmia, a generic version of the popular GLP-1 peptide semaglutide indicated for chronic weight management. The approval of Sevmia introduces an affordable, high-quality generic alternative to the market, significantly expanding patient access to effective weight-loss treatments.

Novo Nordisk presented promising Phase 2 data during the American Diabetes Association Scientific Sessions for its investigational dual amylin and calcitonin receptor agonist (DACRA) peptide, zenagamtide. The trial demonstrated that adults with type 2 diabetes achieved significant HbA1c reductions alongside substantial weight loss of up to 14.6%.

Pfizer has shared promising Phase 2b clinical data demonstrating robust efficacy and a favorable tolerability profile for berobenatide, a monthly dose GLP-1 receptor agonist peptide.

At the American Diabetes Association Scientific Sessions, Antag Therapeutics presented highly encouraging Phase 1 data for AT7687, a first-in-class GIP receptor antagonist peptide. The trial confirmed the peptide's safety and tolerability while validating its mechanisms for managing diabetes and obesity.

Zealand Pharma highlighted remarkable Phase III results from partner Boehringer Ingelheim regarding survodutide, a dual GCGR/GLP-1R agonist peptide. The trial revealed that survodutide achieved a 34% reduction in visceral fat and a 63% reduction in liver fat in individuals living with obesity. Crucially, the peptide achieved these dramatic reductions while successfully minimizing the loss of healthy lean muscle mass.

Ascletis Pharma announced that the US FDA approved its IND application to launch a Phase I clinical trial for ASC35, an investigational, once-monthly subcutaneous GLP-1R/GIPR dual agonist peptide for obesity. ASC35 demonstrated significantly improved weight loss efficacy and a six-fold longer half-life compared to tirzepatide in head-to-head preclinical studies.

Neurology & Pain Management

Neurocrine Biosciences has launched a Phase 1 first-in-human clinical study evaluating NBIP-'2118, a peptide agonist targeting the corticotropin-releasing factor type 2 receptor (CRF2) for weight loss. This potential first-in-class, once-weekly subcutaneous therapy offers a non-incretin mechanism designed to promote fat loss while uniquely preserving or increasing lean muscle mass.

Neuraly Inc. is supporting an investigator-initiated Phase 2 clinical trial evaluating pegsebrenatide (NLY01) in patients with progressive multiple sclerosis. Pegsebrenatide is a long-acting, pegylated GLP-1 receptor agonist peptide designed to target neuroinflammation.

Protagenic Therapeutics released positive clinical updates regarding TCAP-1, a synthetic peptide analog modeled after Teneurin C-terminal Associated Peptide. Designed to treat chronic stress, anxiety, and depression, TCAP-1 works by regulating the brain’s overactive stress response pathways.

Calibr, the translational drug discovery division of Scripps Research, has published promising data regarding CLF065, an optimized, long-acting peptide therapeutic for inflammatory bowel disease. The CLF065 peptide targets the protective intestinal lining to help restore it.

Lateral Pharma has published new preclinical research validating the LANCL1 protein pathway as a highly effective therapeutic target for managing neuropathic pain. By developing peptides that mimic natural signaling through this pathway, the company aims to alleviate chronic pain without the addictive properties of opioids.

Rein Therapeutics announced the strategic expansion of its Phase 2 RE-NEW clinical trial into the United Kingdom, broadening the patient registry for its inhaled peptide therapy for pulmonary fibrosis, LTI-03.

Endocrinology & Bone/Growth Disorders

MBX Biosciences released positive one-year clinical data demonstrating the efficacy of its long-acting peptide candidate for chronic hypoparathyroidism. The engineered peptide prodrug provided stable, continuous regulation of parathyroid hormone levels with convenient, once-weekly dosing.

At ENDO 2026, BioMarin announced three-year data for Voxzogo (vosoritide), a C-type natriuretic peptide, demonstrating its efficacy in treating hypochondroplasia. The company also showcased promising early clinical results for BMN 333, a next-generation peptide candidate aimed at related skeletal dysplasias.

Entera Bio has received encouraging feedback from the FDA regarding 12-month data for EB613, their investigational oral parathyroid hormone (PTH) peptide for osteoporosis. The FDA's alignment on the clinical path forward accelerates Entera's plans for a definitive Phase 3 registrational trial.

Respiratory & Women's Health

A breakthrough study featured in Drug Discovery News highlights what could be the first disease-modifying treatment targeting the root causes of endometriosis. The research focuses on novel peptide pathways capable of selectively inhibiting the growth of endometrial lesions without disrupting systemic hormone levels.

Kither Biotech has successfully finalized its Phase 1 clinical trial evaluating KIT2014, a novel inhaled peptide therapy targeting respiratory illnesses like cystic fibrosis. The trial confirmed that the inhaled peptide formulation was safe, well-tolerated, and capable of effectively delivering local therapeutic action directly to lung tissues.